Active substance
Foscarnet
- SFDA 2
- US FDA 9
- Health Canada 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Foscarnet BOS | 24 mg/ml | Solution for infusion · Intravenous use | 1 Bag | SAR 821.30 | Generic · Prescription | Boston Oncology Arabia | Valid |
| Foscavir | 24 mg/ml | Solution for infusion · Intravenous use | 1 Bottle | SAR 821.30 | NCE · Prescription | Clinigen Healthcare Ltd | Valid |
Indications — CHI Daman Drug Formulary
HUMAN IMMUNODEFICIENCY VIRUS; OTHER CYTOMEGALOVIRAL DISEASES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FOSCAVIR | 6GM/250ML (24MG/ML) | solution · intravenous | CLINIGEN HLTHCARE | Prescription | 27 Sep 1991 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 29 Jan 2021 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML) | solution · intravenous | GLAND | Prescription | 21 Apr 2021 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML) | solution · intravenous | AVET LIFESCIENCES | Prescription | 5 Jun 2023 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML) | solution · intravenous | SCIECURE | Prescription | 29 Nov 2023 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML) | solution · intravenous | AMNEAL | Prescription | 1 Mar 2024 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML) | solution · intravenous | CAPLIN | Prescription | 13 May 2026 |
| FOSCAVIR | 12GM/500ML (24MG/ML) | solution · intravenous | CLINIGEN HLTHCARE | Discontinued | 27 Sep 1991 |
| FOSCARNET SODIUM | 6GM/250ML (24MG/ML); 12GM/500ML (24MG/ML) | solution · intravenous | HOSPIRA | Discontinued | 31 May 2005 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| VOCARVI | 02505924 | 24 MG / ML | SOLUTION · INTRAVENOUS | STERIMAX INC |
Safety signals and safety-related labeling changes
- US FDA 24 Feb 2017 FOSCAVIR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.